Home > Boards > US Listed > Biotechs > Synthetic Biologics, Inc. (SYN)

$SYN SYN-010 is a proprietary, modified-release formulation of

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
SpotOnTrade Member Profile
Member Level 
Followed By 701
Posts 108,886
Boards Moderated 7
Alias Born 08/13/10
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 11/4/2019 4:38:28 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/4/2019 4:21:33 PM
Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results PR Newswire (US) - 11/4/2019 4:10:00 PM
Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019 PR Newswire (US) - 10/28/2019 4:30:00 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 9/26/2019 5:05:45 PM
Synthetic Biologics Strengthens U.S. Patent Coverage of SYN-010, Intended for the Novel Treatment of Irritable Bowel Syndrome... PR Newswire (US) - 9/26/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/6/2019 6:03:48 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/26/2019 5:01:01 PM
Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019 PR Newswire (US) - 8/1/2019 7:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 7/15/2019 5:16:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/1/2019 7:06:03 AM
Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards PR Newswire (US) - 7/1/2019 7:00:00 AM
Sýn hf. : First quarter results in a profit of ISK 670 million GlobeNewswire - 5/15/2019 12:26:39 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/8/2019 5:06:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2019 4:17:37 PM
Synthetic Biologics Reports First Quarter 2019 Operational Highlights and Financial Results PR Newswire (US) - 5/8/2019 4:10:00 PM
Synthetic Biologics to Report 2019 First Quarter Operational Highlights and Financial Results on May 8, 2019 PR Newswire (US) - 4/30/2019 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/3/2019 5:15:49 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 4/3/2019 5:15:25 PM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/1/2019 5:02:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/4/2019 5:03:56 PM
Annual Report (10-k) Edgar (US Regulatory) - 2/27/2019 5:05:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/27/2019 4:19:26 PM
Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results PR Newswire (US) - 2/27/2019 4:10:00 PM
Sýn hf. : Q4 Investors presentation GlobeNewswire - 2/27/2019 3:03:57 PM
SpotOnTrade Member Level  Thursday, 03/21/19 11:56:34 AM
Re: CollegeGrad22 post# 8030
Post # of 8128 
$SYN SYN-010 is a proprietary, modified-release formulation of lovastatin lactone that is intended to reduce methane production by certain microorganisms (M. smithii) in the gut while minimizing disruption to the microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). https://www.syntheticbiologics.com/product-pipeline/syn-010

Nothing I say, post, or do should ever be considered financial advice. I may be holding a long, short or no position. I am NOT or NEVER have I been compensated to post on here or anywhere and all my posts are for entertainment purposes only.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist